USP and Public Policy
Left
Refine Your Search
USP comments in the SIDI comment form on Standardized Information on Dietary Ingredients (SIDI) Protocol.
Learn More
USP respectfully submits comments on the Food and Drug Administration’s (FDA) Final Guidance, Nonproprietary Naming of Biological Products (Final Guidance).
Learn More
USP welcomes the opportunity to provide comments to the U.S. Food and Drug Administration (FDA) concerning approaches around the national opioid crisis.
Learn More
USP appreciates the opportunity to comment on the approval application for the proposed biosimilar to Avastin (bevacizumab).
Learn More
Comments by USP for Conference Room Document Responding to Discussion Paper on Food Integrity and Food Authenticity Prepared by Iran with assistance from Canada and the Netherlands.
Learn More
USP respectfully submits comments on the Food and Drug Administration’s (FDA) Final Guidance, Nonproprietary Naming of Biological Products (Final Guidance).
Learn More
In response to the request from the Commission of Analytical Control and Expansion of Coverage (CCAYAC) within Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS), this…
Learn More
USP appreciates this opportunity to submit comments on FDA’s Draft Guidance on Hazard Analysis and Risk-Based Preventive Controls for Human Food (HARPC Draft Guidance).
Learn More
USP appreciates the opportunity to comment on the Food and Drug Administration's (FDA) issuance of the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With…
Learn More
USP welcomes this opportunity to submit comments on FDA’s planned development of a list of pre-Dietary Supplement Health and Education Act ingredients (preDSHEA list).
Learn More